title: [Hyperbaric oxygen therapy adjunctive to surgical debridement in management of Fournier's gangrene: usefulness of a severity index score in predicting disease gravity and patient survival].
abstract: BACKGROUND
  Hyperbaric oxygen therapy (HBOT) concomitant to surgery has been reported to reduce Fournier's gangrene (FG) mortality compared to exclusive surgical debridement. Most report from centers with relatively few patients using only surgical procedure. To assess efficiency of aggressive debridement with adjunctive HBOT. To evaluate Fournier's gangrene severity score index (FGSI) predictive value.
  
  
  METHODS
  70 Fournier's gangrene (FG) treated by surgical debridement and HBOT. Data were evaluated physical examination findings, admission and final laboratory tests, surgical debridement extent, and antibiotic used. Patients had adjunctive (HBOT). FGSI, developed to assign a score describing the acuity of disease, was used. This index presents patients' vital signs, metabolic parameters (sodium, potassium, creatinine, and bicarbonate levels, and white blood cell count) and computes a score relating to the severity of disease at that time. Data were assessed according to whether the patient survived or died. All patients underwent surgical debridement. Wound debridement was regularly performed in the post operative period.
  
  
  RESULTS
  Of 70 patients, 8 died (11.4%) and 62 survived (88.5%). Difference in age between survivors (median age, 50.0 yr) and non survivors (median age, 54.5 yr) was not significant (p=0.321). Median extent of body surface area involved in necrotizing process in patients who survived and did not survive was 2.4% and 4.9%, respectively (p=0.001). Except for albumin, no significant differences were found between survivors and nonsurvivors. Median admission FGSI scores for survivors and non survivors were 2.1±2.0 and 4.2±3.8, (p=0.331).
  
  
  CONCLUSIONS
  FGSI score did not predict disease severity and the patient's survival. Metabolic aberrations, extent of disease seemed to be important risk factors for predicting FG severity and patient survival.
authors.affiliation: Departamento de Urología, Hospital Militar Universitario, Facultad de Medicina Mohamed V, Rabat, Marruecos. a.janane@yahoo.fr
authors.forename: A
authors.initials: A
authors.lastname: Janane
authors.forename: F
authors.initials: F
authors.lastname: Hajji
authors.forename: T O
authors.initials: TO
authors.lastname: Ismail
authors.forename: J
authors.initials: J
authors.lastname: Chafiqui
authors.forename: M
authors.initials: M
authors.lastname: Ghadouane
authors.forename: A
authors.initials: A
authors.lastname: Ameur
authors.forename: M
authors.initials: M
authors.lastname: Abbar
authors.forename: A
authors.initials: A
authors.lastname: Albouzidi
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003646:Debridement; D018934:Fournier Gangrene / Q000097:blood / Q000382:microbiology / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D006801:Humans; D006931:Hyperbaric Oxygenation; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D008795:Metronidazole